Definitive Healthcare Corp. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. The company provides healthcare commercial intelligence through a SaaS platform; it reported more than 2,900 customers at quarter-end. Financial amounts below are in U.S. dollars, millions, unless stated otherwise. The 2021 comparison reflects Definitive OpCo before the September 2021 IPO and reorganization, so it is not fully comparable to 2022 consolidated results.
Key financial results
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $54.5 | $39.8 | $104.7 | $76.8 |
| Gross profit / GAAP gross margin | $42.8 / 78.4% | $30.0 / 75.2% | $81.6 / 77.9% | $57.5 / 74.8% |
| Operating loss | ($11.2) | ($6.6) | ($22.2) | ($8.8) |
| Consolidated net loss | ($9.6) | ($15.0) | ($22.6) | ($25.5) |
| Adjusted EBITDA / margin | $16.3 / 30% | $14.4 / 36% | $30.3 / 29% | $28.5 / 37% |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $29.1 | $21.9 |
Q2 net loss attributable to Definitive Healthcare Corp. was $5.2 million, or $0.05 per Class A share; the balance of consolidated loss was attributable to noncontrolling interests. Six-month attributable loss was $13.8 million, or $0.14 per share. Adjusted EBITDA and margin are non-GAAP measures; the company reconciles them to GAAP net loss in the filing.
Subscription revenue drove growth: Q2 revenue increased 37% year over year, primarily from expansion with existing customers, new customers, and the Analytical Wizards acquisition. Six-month revenue rose 36%. Subscription revenue was approximately 98% of first-half revenue. Remaining performance obligations were $256.6 million at June 30, including $163.3 million current; the company expected to recognize approximately 64% within the next year.
Liquidity, debt, and cash flow
At June 30, cash and cash equivalents were $228.2 million and short-term investments were $118.2 million, for $346.4 million combined. The $75.0 million revolving facility was undrawn. Current assets were $396.2 million and current liabilities $119.2 million. Operating cash flow for the first half was $29.1 million; investing cash outflow was $177.0 million, including $119.0 million net purchases of short-term investments and $56.5 million for the Analytical Wizards acquisition. Financing cash outflow was $11.1 million.
Term-loan principal was $269.8 million ($267.5 million net of issuance costs); the loan matures in September 2026 and includes an approximately $220 million balloon payment. The effective interest rate was 3.92%; the company reported no revolver borrowings and compliance with financial covenants. Two interest-rate swaps covered $135 million of notional through March 2025. The filing estimates that, absent swaps, a 1 percentage-point rate change would affect first-half interest expense by approximately $1.4 million.
Material changes, outlook, and notable items
- Operating expenses rose 48% in Q2 and 57% in the first half, driven chiefly by hiring, higher stock-based compensation, benefits, and public-company costs. Sales and marketing and product development spending increased substantially. As a result, operating losses widened despite revenue growth.
- Adjusted EBITDA increased in dollars, but its margin declined to 30% in Q2 and 29% for the first half, versus 36% and 37%, respectively, in the prior-year periods.
- Analytical Wizards was acquired on February 18 for total consideration of approximately $99.4 million, including the prior $40 million investment and contingent consideration. Preliminary purchase accounting included $61.5 million of goodwill and $46 million of acquired intangibles; allocations remained provisional. Post-acquisition standalone results were not material.
- The company adopted lease accounting guidance in January. Office exits and lease modifications led to approximately $1.0 million of impairment charges in Q2, and one facility is scheduled to terminate on December 31, 2022.
- Management said it expects cash, investments, operating cash flow, and available borrowing capacity to cover liquidity needs for at least 12 months. It did not provide numerical revenue or earnings guidance in the supplied filing text. Management expects continued investment in sales and marketing and product development; it anticipated higher 2022 sales and marketing and general and administrative costs relative to revenue.
- Risks and contingencies include variable-rate debt, the ability to sustain customer acquisition and expansion, acquisition integration and provisional purchase accounting, and the tax receivable agreement. The TRA liability was $155.9 million; the company generally owes certain former owners 85% of realized or deemed tax savings. Management noted tax-basis adjustments and TRA payments may be substantial and may accelerate under specified events. Deferred tax assets were subject to a valuation allowance.
- Management reported no material change in risk factors from its 2021 Form 10-K, no material adverse effect expected from ordinary-course legal matters, and no off-balance-sheet arrangements. COVID-19 had not materially adversely affected the business to date, but longer-term effects remained uncertain.
Important facts for investors to verify
- Whether subscription growth, customer expansion, renewals, and retention remain strong; the filing does not provide a current NDR value.
- Whether expense growth and stock-based compensation moderate enough to support improved adjusted margins, and how non-GAAP adjustments compare with recurring costs.
- Final Analytical Wizards purchase-price allocation, integration performance, and any contingent earn-out payments.
- Cash generation and investment needs relative to the term-loan amortization and approximately $220 million maturity balloon; also monitor interest-rate exposure and swap coverage.
- Potential TRA cash obligations, tax-asset recoverability, and dilution/noncontrolling-interest effects from LLC-unit exchanges and equity awards.